NEW YORK, Aug. 3, 2012 /PRNewswire/ -- Internationally recognized Mount Sinai robotic prostate cancer surgeon, Dr. David Samadi, continues to "walk the talk" with his quarterly patient newsletter. The latest issue takes a frank look at the prostate-specific antigen (PSA) test and the changing face of prostate cancer screening and prostate cancer treatment.
RoboticOncology.com: August 2012 Newsletter - PSA Controversy and What You Need to Know About Prostate Cancer - Click Here
The reputation of the PSA blood test seems to fluctuate monthly. Shortly after a U.S. government task force firmly advised against routine screening of healthy men, new reports emerge in support of the PSA. Some government data now points to PSA success in reducing the number of advanced-stage prostate cancer diagnoses by as much as three times.
The newsletter is just another example of the lifelong commitment of care that Dr. Samadi and his team make to each patient. "Even when patients overcome prostate cancer, information is still vital," he stresses, "What we share with our patients could be infinitely helpful to other members of their family – their brothers, their sons. We take that responsibility very seriously."
Dr. Samadi routinely supports use of the PSA test, but in his summer newsletter he takes a candid look at just how far the PSA can take us and shares exciting news about the future of prostate cancer diagnostics.
Dr. Samadi's PSA Evolution article touches on the heavily debated limitations of the PSA, chief among them its inability to accurately stage the disease upon diagnosis. Without precision regarding a man's prostate cancer severity, treatment decisions, including whether or not to have robotic prostatectomy surgery, are up to the surgeon's and patient's best call.
With an eye to the future, Dr. Samadi gives patients a broad overview of prostate cancer screening advancements and how we may soon have the power to make even more informed treatment decisions.
"We hear a lot about gene therapy," says Dr. Samadi, "and it truly is the future of medicine. Genetic analysis teaches us more about prostate cancer every day. Methodology involving CNVs and various proteins in the body are going to change the way we diagnose prostate cancer and fight it."
Copy Number Variations (CNVs) in prostate cancer tumor cells are soon-to-be sources of guidance for predicting how the disease will progress, while SPDEF proteins are beginning to define what enables – and ultimately, prevents – metastases.
The Robotic Oncology Newsletter also reminds patients how PSA Velocity Risk Count and post-treatment PSA screening contribute to lifelong wellness.
Dr. David Samadi is Vice Chairman of the Department of Urology and Chief of Robotics and Minimally Invasive Surgery at Mount Sinai Medical Center in New York and innovator of the SMART technique (Samadi Modified Advanced Robotic Technique) robotic prostatectomy surgery.